

Item 13(i)

Date	Tuesday, 14 November 2017
-------------	---------------------------

Title of paper	CCG Finance Report M6
-----------------------	------------------------------

Presenter	Shelley Martin, H&F CCG				
Author	Shelley Martin, Head of Finance, H&F CCG				
Responsible Director	Keith Edmunds, CWHHE CFO Approved report: No				
Clinical Lead	None				
Confidential	Yes	<input type="checkbox"/>	No	<input checked="" type="checkbox"/>	Items are only confidential if it is in the public interest for them to be so

The Committee is asked to:

- **Note** the financial position reported for H&F CCG at month 6.

Summary of purpose and scope of report

- To update and inform the Governing Body about the financial performance of the CCG. The paper highlights the achievement of statutory duties and any material variances from plan – at month 6 the CCG is reporting on plan both YTD and forecast outturn.
- The annual budget has been updated in month 6 to reflect the allocation changes as at month 6 – a topslice of £0.4m to contribute to the London Healthy Partnership programme.
- The planned surplus remains unchanged at £0.93m in year, and cumulative £6.24m to carry forward to 18/19.
- The key concerns are:
 - (i) the forecast relies on a significant level of backended QIPP and release of non recurrent gains from the balance sheet. Whilst this allows the CCG to report on plan there is a high level of net risk in delivering this position
 - (ii) the mitigations in year are largely non recurrent and so the underlying position going into 18/19 is forecast to be in the range of £0.5m - £5m deficit depending on the assumptions made regarding backended QIPP.

Item 13(i)

Quality & Safety/ Patient Engagement/ Impact on patient services:
None

Finance, resources and QIPP
None

Equality / Human Rights / Privacy impact analysis
None

Risk	Mitigating actions
None	

Supporting documents
None

Governance and reporting		
(list committees, groups, other bodies in your CCG or other CCGs that have discussed the paper)		
Committee name	Date discussed	Outcome
Finance & Performance Committee	24 October 2017	Noted